Here, we investigated to what degree CD33 transcript variants are found in AML, what the endocytic properties are of these variants, and whether their co-expression affects the ability of CD33FL to serve as a target for therapeutic antibodies. The gene discussed is CD33; the disease is acute myeloid leukemia.